XOMA (XOMA)
(Delayed Data from NSDQ)
$25.03 USD
-0.48 (-1.88%)
Updated May 20, 2024 04:00 PM ET
After-Market: $25.47 +0.44 (1.76%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.03 USD
-0.48 (-1.88%)
Updated May 20, 2024 04:00 PM ET
After-Market: $25.47 +0.44 (1.76%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
Xoma (XOMA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xoma (XOMA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will XOMA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in XOMA.
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Will XOMA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor XOMA.
Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Firm's First Profit Can Mean Big Returns for Investors
by Benjamin Rains
We are already roughly halfway through second-quarter 2019 earnings season. This means now could be a great time to look at a 'First Profit' stock screen.
Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.
Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View
by Zacks Equity Research
Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.